News | May 20, 2013

Medicare Establishes Billing Code for InSightec's MR-Guided Focused Ultrasound

Therapy treats pain palliation of bone metastases

 

May 20, 2013 — InSightec Ltd. announced that the U.S. Centers for Medicare & Medicaid Services (CMS), a federal agency within the U.S. Department of Health and Human Services (HHS), has created a new billing code for magnetic resonance (MR) guided focused ultrasound treatment of pain palliation of metastatic bone lesions and has established a Medicare payment rate for hospital outpatient departments.

InSightec's ExAblate received U.S. Food and Drug Administration (FDA) approval for pain palliation of metastatic bone lesions in October 2012 and is the only MRgFUS system that is FDA approved for this indication. The approval was based on a two-arm randomized controlled trial comparing patients undergoing ExAblate MRgFUS for palliation of painful bone metastases with patients undergoing a placebo treatment.

ExAblate combines therapeutic acoustic ultrasound waves and continuous guidance and treatment monitoring with magnetic resonance imaging (MRI). Physicians use the MRI to plan and guide the therapy and monitor treatment outcome. The focused ultrasound acoustic energy destroys the nerves causing the pain, resulting in rapid pain reduction.

According to the American Cancer Society, more than two-thirds of metastatic breast and prostate cancers and up to 30 percent of metastatic lung, bladder and thyroid cancers spread to the bones. Close to 30 percent of patients with bone metastases either do not respond to radiation therapy or will be unable to undergo radiation for pain relief. ExAblate provides a single session, non-invasive option that is highly effective with a low complication rates.

"We are extremely pleased with CMS' decision to provide a code and establish payment for MR guided focused ultrasound for bone metastases," said Kobi (Jackob) Vortman, president and chief executive officer of InSightec. "This is particularly important for the many cancer patients with crippling bone pain who are no longer eligible for radiation treatment. ExAblate is a safe and effective adjunctive treatment which enables patients to more quickly reduce their pain and their reliance on narcotic pain medications."

The new code, C9734, became effective April 1, 2013, and it was assigned to Ambulatory Payment Classification (APC) group 0067 (Level III Stereotactic Radiosurgery, MRgFUS and MEG).

ExAblate is the only MRgFUS system with FDA approval for pain palliation of bone metastases and for uterine fibroids. In addition, it has received European CE marking for uterine fibroids, bone metastases, benign bone tumors, adenomyosis, essential tremor, tremor-dominant Parkinson's disease and neuropathic pain. FDA approved clinical trials are ongoing for essential tremor, Parkinson's disease and prostate cancer.

For more information: us.insightec.com

Related Content

The Revolution Apex intelligent computed tomography (CT) scanner

The Revolution Apex intelligent computed tomography (CT) scanner. Image courtesy of GE Healthcare.

News | RSNA | October 18, 2019
At the 2019 annual meeting of the Radiological Society of North America (RSNA 2019), Dec. 1-6 in Chicago, GE Healthcare...
Guerbet Signs Agreement With Icometrix for Exclusive Distribution of Icobrain
News | Neuro Imaging | October 16, 2019
Guerbet announced it has signed an exclusive agreement with Icometrix for the distribution in France, Italy and Brazil...
Subtle Medical Receives FDA 510(k) Clearance for AI-powered SubtleMR
Technology | Artificial Intelligence | October 16, 2019
Subtle Medical announced 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market SubtleMR. SubtleMR...
Using Compressed SENSE for faster MRI scans, healthcare providers can transform their radiology workflow.

Using Compressed SENSE for faster MRI scans, healthcare providers can transform their radiology workflow.

Sponsored Content | Case Study | Magnetic Resonance Imaging (MRI) | October 16, 2019
Since the introduction of magnetic resonan...
Canon Medical Receives FDA Clearance for Vantage Orian 1.5T MRI

Canon Medical Receives FDA Clearance for Vantage Orian 1.5T MRI

Feature | Magnetic Resonance Imaging (MRI) | October 09, 2019 | By Jeff Zagoudis
Patient Treatments With ViewRay's MRIdian Linac Begin in New England
News | Image Guided Radiation Therapy (IGRT) | October 08, 2019
ViewRay Inc. announced today that patient treatments are scheduled to begin in Boston with ViewRay's MRIdian Linac...
Machine Learning Could Offer Faster, More Precise Cardiac MRI Scan Results
News | Magnetic Resonance Imaging (MRI) | September 25, 2019
Cardiac magnetic resonance imaging (MRI) analysis can be performed significantly faster with similar precision to...
Colorado Orthopedic Clinic Adds Canon Medical Vantage Galan 3T MRI to Frisco Clinic Location
News | Magnetic Resonance Imaging (MRI) | September 25, 2019
The Steadman Clinic has added Canon Medical Systems USA Inc.’s Vantage Galan 3T magnetic resonance (MR) system to the...
Imaging Biometrics and Medical College of Wisconsin Awarded NIH Grant
News | Neuro Imaging | September 09, 2019
Imaging Biometrics LLC (IB), in collaboration with the Medical College of Wisconsin (MCW), has received a $2.75 million...
ASNC Announces Multisocietal Cardiac Amyloidosis Imaging Consensus
News | Cardiac Imaging | September 09, 2019
September 9, 2019 — The American Society of Nuclear Cardiology (ASNC) published a new expert consensus document along